Ana Matas-Garcia

Dr. Ana Matas-Garcia

Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Ana Matas-GarciaAna Matas-Garcia
Ana Matas-Garcia
JMJose C. Milisenda
Jose C. Milisenda
Gerard EspinosaGerard Espinosa
Gerard Espinosa
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
SPSergio Prieto-González
Sergio Prieto-González
Dermatomyositis is a systemic vasculopathy mainly affecting skin, muscle and lung, but may affect the gastrointestinal tract. We aim to describe clinical characteristics of patients with severe gastrointestinal involvement related to dermatomyositis in our center and medical literature. We retrospectively analysed these patients in our center, including cases of erosions/ulcers, perforation or digestive bleeding. Reported cases from April 1990 to April 2021 were reviewed through PubMed and Cochrane. From our cohort (n = 188), only 3 presented gastrointestinal compromise. All were women (10, 46 and 68 years). The initial symptom was abdominal pain and all had ≥2 episodes of digestive bleeding. All died due to complications of gastrointestinal involvement. Available pathological samples showed vascular ectasia. From the literature review (n = 50), 77% were women with a mean age of 49 years and the main symptom was abdominal pain (65%). All presented active muscular and cutaneous involvement at complication diagnosis. Mortality was 41.7%. The underlying lesion was perforation or ulcer (n = 22), intestinal wall thickening (n = 2), macroscopic inflammation (n = 2) or intestinal pneumatosis (n = 15). In 13 cases, vasculitis was described. Gastrointestinal involvement in dermatomyositis denotes severity, so an early intensive treatment is recommended. Pathological findings suggest that the underlying pathophysiological mechanism is a vasculopathy and not a true vasculitis.

12 May 2020 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
FSFerran Seguí
Ferran Seguí
Lidia Gonzalez-QueredaLidia Gonzalez-Quereda
Lidia Gonzalez-Quereda
ASAurora Sanchez
Aurora Sanchez
Ana Matas-GarciaAna Matas-Garcia
Ana Matas-Garcia
GGGloria Garrabou
Gloria Garrabou
JMJose C. Milisenda
Jose C. Milisenda

22 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSSinziana Stanescu
Sinziana Stanescu
PCPatricia Correcher-Medina
Patricia Correcher-Medina
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
OLOlga Alonso Luengo
Olga Alonso Luengo
LMLuis Maria Arto Millan
Luis Maria Arto Millan
MOMar o'callaghan
Mar o'callaghan
This was a retrospective, multicenter study that aimed to report the characteristics of type 3 Gaucher disease (GD3) patients in Spain, including the genotype, phenotype, therapeutic options, and treatment responses. A total of 19 patients with GD3 from 10 Spanish hospitals were enrolled in the study (14 men, 5 women). The median age at disease onset and diagnosis was 1 and 1.2 years, respectively, and the mean age at follow-up completion was 12.37 years (range: 1–25 years). Most patients exhibited splenomegaly (18/19) and hepatomegaly (17/19) at the time of diagnosis. The most frequent neurological abnormalities at onset were psychomotor retardation (14/19) and extrinsic muscle disorders (11/19), including oculomotor apraxia, supranuclear palsy, and strabismus. The L444P (c.1448T>C) allele was predominant, with the L444P (c.1448T>C) homozygous genotype mainly associated with visceral manifestations like hepatosplenomegaly, anemia, and thrombocytopenia. All patients received enzyme replacement therapy (ERT); other treatments included miglustat and the chaperone (ambroxol). Visceral manifestations, including hepatosplenomegaly and hematological and bone manifestations, were mostly controlled with ERT, except for kyphosis. The data from this study may help to increase the evidence base on this rare disease and contribute to improving the clinical management of GD3 patients.

1 December 2022 in Revista De Neurologia
Verified
Journal Article
Open access
Ana Matas-GarciaAna Matas-Garcia
Ana Matas-Garcia
ATAdrián Téllez
Adrián Téllez
SFSara Fernández
Sara Fernández
ESEmilio Salgado
Emilio Salgado
PCPedro Castro
Pedro Castro
Introduction. Disulfiram-induced-encephalopathy is a rare complication that has been well described in adults. Although it usually occurs in acute intoxication with high doses of disulfiram, late onset encephalopathy has also been reported. Some authors propose the inhibition of dopamine beta-hydroxylase mediated by toxic metabolites of disulfiram as the main responsible, but the exact mechanism remains unclear. The aim of this report was to describe the clinical and neuroimaging findings in an unusual case of acute encephalitis due to disulfiram toxicity associated to chronic intranasal consume. Case report. A chronic alcoholic who referred snorted use of a very high dose of disulfiram without simultaneous alcohol intake developed an acute encephalopathy with a rapidly progressive respiratory failure. A characteristic neuroimage finding consisting in extensive bilateral symmetric involvement of both pallidal nuclei was described. Recovery and neurologic improvement were slow. Two months after the intoxication, the patient still had slight intentional tremor and a scheduled magnetic resonance imaging. showed evolution of symmetrical areas of cytotoxic edema to necrosis. Conclusion. Disulfiram-induced neurotoxicity must be suspect during chronic therapy with disulfiram or after acute ingestion of high doses. Symptoms such as symmetric sensory and motor neuropathy, confusion, catatonia, parkinsonism, ataxia, choreoathetosis, seizures and encephalopathy should make us rule out this disorder. A brain imaging test should be performed in these patients since a characteristic involvement of both nuclei pallidus has been described, but it is not present in all patients.

29 December 2025 in Current Treatment Options in Rheumatology
Verified
Journal Article
Open access
PDF file
ASAlbert Selva-O’cAllaghan
Albert Selva-O’cAllaghan
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
AGAlbert Gil-Vila
Albert Gil-Vila
Ana Matas-GarciaAna Matas-Garcia
Ana Matas-Garcia
CEClara Edo
Clara Edo
IPIago Pinal-Fernández
Iago Pinal-Fernández
Purpose of Review: Inflammatory myopathies are a heterogeneous group of systemic autoimmune disorders with highly variable clinical presentations. The limited number of clinical trials has hindered the development of strong evidence-based management strategies. Therefore, there is a pressing need for consensus-driven treatment guidelines tailored to the various clinical and immunological phenotypes. This review combines existing published guidelines with the authors’ clinical experience to provide a comprehensive, pragmatic approach to management. Recent Findings: A comparative review of existing treatment guidelines was recently published, revealing significant heterogeneity in therapeutic approaches and recommendations. This observation is consistent with our own experience during a multidisciplinary meeting, primarily involving internal medicine specialists and rheumatologists. Furthermore, recent clinical trials and observational studies investigating novel therapies offer promising prospects that could influence future clinical decision-making. Summary: Although establishing a unified therapeutic algorithm remains challenging, this review aims to translate current knowledge into clinical practice by integrating existing guidelines, our own clinical experience, and the most recent evidence published on the topic.

Verified
Journal Article
Open access
PDF file
ARArnau Gonzalez Rodriguez
Arnau Gonzalez Rodriguez
BBBlanca Barrau-Martínez
Blanca Barrau-Martínez
APAdriana Pané
Adriana Pané
RGRosa Maria López Galera
Rosa Maria López Galera
ETEster Tobias
Ester Tobias
RLRafael Llorach
Rafael Llorach
Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by phenylalanine hydroxylase deficiency, leading to phenylalanine (Phe) accumulation and neurological dysfunction if untreated. While metabolomics holds promise for biomarker discovery in PKU, few studies have examined urinary metabolites using untargeted approaches. This study applied untargeted metabolomics using HPLC-QTOF-MS to analyze urine from 36 adult patients with PKU and 34 healthy controls. Biomarker Analysis was performed with MetaboAnalyst 6.0. A total of 73 significant metabolites (FDR < 0.05; VIP > 1) were identified, with 29 upregulated and 44 downregulated in PKU. A 23% of these metabolites were related to Phe metabolism, while 77% were associated with alterations across more than 10 metabolic pathways, including leucine and tryptophan metabolism, acylcarnitines, vitamins, and diet- or microbiota-derived compounds, among others. Specifically, upregulated metabolites with an AUC > 0.9 included several Phe-derived compounds, the nucleoside 8-hydroxy-7-methylguanine, and indole compounds (1H-indole-3-carboxaldehyde). Conversely, downregulated metabolites with an AUC > 0.9 included N-acetyl(iso)leucine and a heptenoylcarnitine isomer. The Random Forest-based model demonstrated enhanced predictive performance when integrating 10 metabolites, supporting their potential utility as biomarkers for PKU. These findings improve the biological understanding of metabolic disturbances beyond Phe, and may support the development of new therapeutic and dietary strategies.